Academic and Community Cancer Research United

A cancer research network conducting clinical trials that translate the latest

discoveries into new therapies for cancer treatment and symptom management

WHO WE ARE


  Our Members

Our network includes more than 100 leading academic medical centers and community oncology practices in the United States and internationally.     Our members >

 Clinical Trials

ACCRU conducts industry-sponsored and investigator-initiated, phase II and III cancer treatment and symptom management trials across many types of cancer.     Clinical trials >

  Services

ACCRU offers a full range of clinical trial development and management services – from protocol development, to regulatory management, to data analysis and biorepository and correlative laboratory services.    Services >

NEWS


MEMBER SPOTLIGHT


Protocol: Phase II Trial of Abemaciclib and T-DM1 in Women and Men with HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment with a Taxane, Trastuzumab and Pertuzumab

 

This phase II trial studies how well T-DM1 with or without abemaciclib works for the treatment of HER2-positive breast cancer that has spread to other places in the body. T-DM1 is a monoclonal antibody called trastuzumab that is linked to a chemotherapy drug called DM1. Trastuzumab attaches to HER2-positive cancer cells in a targeted way and delivers DM1 to kill them.  Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and abemaciclib may work better in treating patients with breast cancer compared to T-DM1 or abemaciclib alone.

 

It is anticipated that this trial will open at several centers throughout the United States in late 2020. For more information, visit https://clinicaltrials.gov/ct2/show/NCT04351230

 

ACCRU Member Investigator/Study Chair: Ciara C. O’Sullivan, M.B. Bch.

 

This trial is led by Ciara C. O’Sullivan, M.B.Bch., a consultant in the Department of Medical Oncology and an assistant professor of oncology at Mayo Clinic in Rochester, Minnesota.

 

Dr. O’Sullivan’s research focuses on the mechanisms of endocrine resistance in advanced hormone receptor positive breast cancer and novel treatment approaches in patients with early and advanced stage HER2-positive breast cancer. She has written several investigator-initiated trials incorporating her research interests.

 

Dr. O’Sullivan received her Bachelor of Medicine and Bachelor of Surgery and Bachelor of Obstetrics degree at University College Dublin, Ireland. She completed an Internal Medicine Residency and Oncology Fellowship at the Royal College of Physicians of Ireland in Dublin, as well as an Oncology Fellowship at the National Cancer Institute in Bethesda, Maryland.

 

Dr. O’Sullivan is the recipient of a 2018 Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) Career Development Award, a 2014 ASCO Merit Award, and a 2013 San Antonio Breast Cancer Symposium Clinical Scholarship.